PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in
children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes
implicated in glutamatergic signaling and neuronal activity. PART B will assess subjects who
do not have CNVs in any of the specific gene mutation(s) implicated in glutamatergic
signaling and neuronal connectivity.
Phase:
Phase 2
Details
Lead Sponsor:
Aevi Genomic Medicine Aevi Genomic Medicine, LLC, a Cerecor company